1. Home
  2. ANIP vs DFIN Comparison

ANIP vs DFIN Comparison

Compare ANIP & DFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANIP
  • DFIN
  • Stock Information
  • Founded
  • ANIP 2001
  • DFIN 1983
  • Country
  • ANIP United States
  • DFIN United States
  • Employees
  • ANIP N/A
  • DFIN N/A
  • Industry
  • ANIP Biotechnology: Pharmaceutical Preparations
  • DFIN Other Consumer Services
  • Sector
  • ANIP Health Care
  • DFIN Consumer Discretionary
  • Exchange
  • ANIP Nasdaq
  • DFIN Nasdaq
  • Market Cap
  • ANIP 1.4B
  • DFIN 1.2B
  • IPO Year
  • ANIP N/A
  • DFIN N/A
  • Fundamental
  • Price
  • ANIP $66.15
  • DFIN $64.40
  • Analyst Decision
  • ANIP Strong Buy
  • DFIN Strong Buy
  • Analyst Count
  • ANIP 8
  • DFIN 3
  • Target Price
  • ANIP $80.13
  • DFIN $68.67
  • AVG Volume (30 Days)
  • ANIP 246.6K
  • DFIN 248.5K
  • Earning Date
  • ANIP 08-05-2025
  • DFIN 07-30-2025
  • Dividend Yield
  • ANIP N/A
  • DFIN N/A
  • EPS Growth
  • ANIP N/A
  • DFIN N/A
  • EPS
  • ANIP N/A
  • DFIN 3.01
  • Revenue
  • ANIP $674,068,000.00
  • DFIN $779,600,000.00
  • Revenue This Year
  • ANIP $30.52
  • DFIN $1.99
  • Revenue Next Year
  • ANIP $7.40
  • DFIN $4.64
  • P/E Ratio
  • ANIP N/A
  • DFIN $21.30
  • Revenue Growth
  • ANIP 30.27
  • DFIN N/A
  • 52 Week Low
  • ANIP $52.50
  • DFIN $37.80
  • 52 Week High
  • ANIP $77.00
  • DFIN $71.01
  • Technical
  • Relative Strength Index (RSI)
  • ANIP 58.88
  • DFIN 80.71
  • Support Level
  • ANIP $63.17
  • DFIN $61.12
  • Resistance Level
  • ANIP $66.18
  • DFIN $64.55
  • Average True Range (ATR)
  • ANIP 1.77
  • DFIN 1.06
  • MACD
  • ANIP 0.07
  • DFIN 0.11
  • Stochastic Oscillator
  • ANIP 75.27
  • DFIN 93.32

About ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

Share on Social Networks: